Loading data for DERM — first visit, this takes a few seconds.
Journey Medical Corporation
7.23 +0.14 (1.97%)
- Рыночная капитализация
- $204.3M
- Объём торгов
- 168K
- Следующая дата отчётности
- Nov 11, 2026
Journey Medical Corporation (DERM): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $15.96M | n/a | +21.48% |
| EPS | -$0,01 | +$0,01 | +93.75% |
Метрики
- Бид
- 5.17
- Выручка (TTM)
- 68.2M
- Чистая прибыль (TTM)
- -6.1M
- 1.10
- -0.22
- n/a
- -120.67
- P/B (TTM)
- 6.24
- P/S (TTM)
- 3.00
- Дата отчёта
- Nov 11, 2026
- Аск
- 9.24
- Объём торгов
- 167,997
- Ср. объём (20д)
- 242,456
- Открытие
- 7.18
- Пред. закрытие
- 7.09
- Диапазон дня
- 7.06 - 7.41
- Диапазон за 52 недели
- 4.31 - 9.55
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- n/a
О компании Journey Medical Corporation
Профиль →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.